文献速递分子诊断临床免疫质量管理与危急值

铜死亡相关循环非编码RNA作为肿瘤诊断与预后生物标志物

Cuproptosis-related circulating non-coding RNAs as diagnostic and prognostic biomarkers in oncology.
PubMed 文献 · Clin Chim Acta · 2026-04-19

本文综述铜死亡相关循环非编码RNA(ncRNA)在人类恶性肿瘤中的诊断与预后价值,强调其与临床化学和检验医学的关联。文章汇总了此类ncRNA与铜死亡关键调控因子、肿瘤分期、治疗反应及生存结局的证据,并讨论标本基质选择、分析前变异、归一化策略及跨平台验证等实验室实施因素。总体认为需经分析验证的工作流程、标准化报告及前瞻性临床验证才能常规应用。

要点

  • 铜死亡相关循环ncRNA在肿瘤早期检测、鉴别诊断和风险分层中具潜在价值。
  • 标本基质(血清、血浆、细胞外囊泡组分)及分析前变异影响检测可靠性。
  • 临床转化需标准化归一化策略、跨平台分析验证和前瞻性临床验证。

核心结论

  • 铜死亡相关循环ncRNA是有前景的肿瘤液体活检标志物,但常规应用尚需分析验证与前瞻性临床验证。

研究设计与样本

  • 综述,评估铜死亡相关循环ncRNA在人类恶性肿瘤中的诊断与预后效用,侧重临床化学与检验医学相关性。

主要发现

  • 循环ncRNA与铜死亡关键调控因子、肿瘤分期、治疗反应及生存结局相关。
  • 此类ncRNA在早期检测、鉴别诊断、风险分层和纵向疾病监测中具潜在作用,包括相对于传统肿瘤标志物的价值。

关键数值与推荐

  • 标本基质选择涉及血清、血浆和细胞外囊泡相关组分。
  • 需考虑分析前变异、归一化策略及跨平台分析验证等实验室因素。
  • 多模态诊断模型、人工智能和数据驱动分析框架可能改善标志物解读并支持标准化。

临床怎么用

  • 临床实施需建立分析验证的工作流程和标准化报告。
  • 解读标志物时应考虑标本基质、分析前变异和归一化策略的影响。

局限性

  • 将铜死亡相关ncRNA特征转化为常规诊断实践仍需前瞻性临床验证。
  • 当前证据尚不足以支持常规临床应用,需标准化报告和分析验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cuproptosis is a recently described copper-dependent form of regulated cell death linked to mitochondrial metabolic stress and is emerging as a biologically relevant pathway in cancer. Circulating noncoding RNAs (ncRNAs), such as microRNAs, long noncoding RNAs and circular RNAs, can be quantified in body fluids and are potential liquid biopsy markers in laboratory medicine. This review evaluates the diagnostic and prognostic utility of cuproptosis-related circulating ncRNAs across human malignancies, with an emphasis on their relevance to clinical chemistry and diagnostic laboratory medicine. We synthesize current evidence linking these circulating ncRNAs to key regulators of cuproptosis, tumor stage, treatment response, and survival outcomes. We further examine their potential roles in early detection, differential diagnosis, risk stratification, and longitudinal disease monitoring, including their value relative to conventional tumor markers. The review highlights laboratory factors affecting clinical implementation, including specimen matrix selection (serum, plasma, and extracellular vesicle-associated fractions), preanalytical variability, normalization strategies, and cross-platform analytical validation. We also discuss how multimodal diagnostic models, artificial intelligence, and data-driven analytical frameworks may improve biomarker interpretation and support standardization. Overall, translating cuproptosis-related ncRNA signatures into routine diagnostic laboratory practice will require analytically validated workflows, standardized reporting, and prospective clinical validation. This review provides a laboratory medicine-focused framework for understanding the opportunities and current limitations of cuproptosis-related circulating ncRNAs as emerging biomarkers in oncology.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Afzal O, Afzal M, Goud P, et al. Cuproptosis-related circulating non-coding RNAs as diagnostic and prognostic biomarkers in oncology. Clin Chim Acta. 2026. PMID: 42014012. doi:10.1016/j.cca.2026.121012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。